Case Reports Hematopathology 2025 Exercise 3: TP53-Negative (Wild-type) Acute/Pure Erythroid Leukemia and Erythroid Sarcoma

Authors

Jason X. Cheng, MD, PhD

Peng Wang, MD, PhD

Sandeep Gurbuxani, MD, PhD

Girish Venkataraman, MD

Angela Lager, PhD

Daniel A. Arber, MD

Department of Pathology

University of Chicago

Chicago, Illinois

Primary Audience: Pathologists and Clinical Scientists
Secondary Audience: Residents, Laboratory Technologist/Scientist (Includes all sub-specialty areas), Students, Pathologist Assistants,  Laboratory Directors and Educators

Upon completion of this activity, you will be able to:

·       know about the history and the evolving classification of AEL/PEL;

·       understand the difference in the AEL/PEL classification between the current 5th edition WHO and the 2022 ICC classifications;

·       recognize the distinct clinicopathologic features of TP53- and TP53+ AEL/PEL and ES as well as benign erythroid proliferation/hyperplasia;

·       be familiar with the difficulties and pitfalls in diagnosis of TP53- AEL/PEL and ES as well as their associated typical genetic alterations; and

·       know how to conduct appropriate morphological, immunophenotypic, molecular and genetic studies for differential diagnosis of TP53- and TP53+ ES and AEL/PEL and other mimics.